Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells
Arianna Moiani,Gil Letort,Sabrina Lizot,Anne Chalumeau,Chloe Foray,Tristan Felix,Diane Le Clerre,Sonal Temburni-Blake,Patrick Hong,Sophie Leduc,Noemie Pinard,Alan Marechal,Eduardo Seclen,Alex Boyne,Louisa Mayer,Robert Hong,Sylvain Pulicani,Roman Galetto,Agnès Gouble,Marina Cavazzana,Alexandre Juillerat,Annarita Miccio,Aymeric Duclert,Philippe Duchateau,Julien Valton
DOI: https://doi.org/10.1038/s41467-024-49353-3
IF: 16.6
2024-06-11
Nature Communications
Abstract:Sickle cell disease is a devastating blood disorder that originates from a single point mutation in the HBB gene coding for hemoglobin. Here, we develop a GMP-compatible TALEN-mediated gene editing process enabling efficient HBB correction via a DNA repair template while minimizing risks associated with HBB inactivation. Comparing viral versus non-viral DNA repair template delivery in hematopoietic stem and progenitor cells in vitro, both strategies achieve comparable HBB correction and result in over 50% expression of normal adult hemoglobin in red blood cells without inducing β-thalassemic phenotype. In an immunodeficient female mouse model, transplanted cells edited with the non-viral strategy exhibit higher engraftment and gene correction levels compared to those edited with the viral strategy. Transcriptomic analysis reveals that non-viral DNA repair template delivery mitigates P53-mediated toxicity and preserves high levels of long-term hematopoietic stem cells. This work paves the way for TALEN-based autologous gene therapy for sickle cell disease.
multidisciplinary sciences